The rational application of liquid biopsy based on next‐generation sequencing in advanced non‐small cell lung cancer
Abstract Background Plasma and tissue biopsy have both used for targeting actionable driver gene mutations in lung cancer, whose concordance is imperfect. A reliable method to predict the concordance is urgently needed to ease clinical application. Methods A total of 1012 plasma samples, including 5...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-03-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.5410 |
| _version_ | 1797866842855833600 |
|---|---|
| author | Chenglong Zhao Jianghua Li Yongchang Zhang Rui Han Yubo Wang Li Li Yimin Zhang Mengxiao Zhu Jie Zheng Haiwei Du Chen Hu Chengzhi Zhou Nong Yang Shangli Cai Yong He |
| author_facet | Chenglong Zhao Jianghua Li Yongchang Zhang Rui Han Yubo Wang Li Li Yimin Zhang Mengxiao Zhu Jie Zheng Haiwei Du Chen Hu Chengzhi Zhou Nong Yang Shangli Cai Yong He |
| author_sort | Chenglong Zhao |
| collection | DOAJ |
| description | Abstract Background Plasma and tissue biopsy have both used for targeting actionable driver gene mutations in lung cancer, whose concordance is imperfect. A reliable method to predict the concordance is urgently needed to ease clinical application. Methods A total of 1012 plasma samples, including 519 with paired‐tissue biopsy samples, derived from lung adenocarcinoma patients were retrospectively enrolled. We assessed the associations of several clinicopathological characteristics and serum tumor markers with the concordance between plasma and tissue biopsies. Results When carcinoembryonic antigen (CEA) levels were higher than thresholds of 15.01 ng/ml and 51.15 ng/ml, the positive predictive value of concordance reached 90% and 95%, respectively. When CEA levels were lower than thresholds of 5.19 ng/ml and 3.26 ng/mL, the negative predictive value of concordance reached 45% and 50%. The performance of CYFRA21‐1 in predicting concordance was similar but inferior to CEA (AUC: 0.727 vs. 0.741, p = 0.633). The performance of CEA combined with CYFRA21‐1 in predicting the concordance was similar to that of the combination of independent factors derived from the LASSO regression model (AUC: 0.796 vs. 0.818, p = 0.067). CEA (r = 0.47, p < 0.01) and CYFRA21‐1 levels (r = 0.45, p < 0.05) were significantly correlated with the maximum variant allele frequency, respectively. Conclusions CEA combined with CYFRA21‐1 could effectively predict the concordance between plasma and tissue biopsies, which could be used for evaluating the priority of plasma and tissue biopsies for gene testing to timely guide clinical applications in advanced lung adenocarcinoma patients. |
| first_indexed | 2024-04-09T23:31:51Z |
| format | Article |
| id | doaj.art-7227b384d7204f0f8ca810ea46cf7bf3 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-09T23:31:51Z |
| publishDate | 2023-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-7227b384d7204f0f8ca810ea46cf7bf32023-03-21T05:20:40ZengWileyCancer Medicine2045-76342023-03-011255603561410.1002/cam4.5410The rational application of liquid biopsy based on next‐generation sequencing in advanced non‐small cell lung cancerChenglong Zhao0Jianghua Li1Yongchang Zhang2Rui Han3Yubo Wang4Li Li5Yimin Zhang6Mengxiao Zhu7Jie Zheng8Haiwei Du9Chen Hu10Chengzhi Zhou11Nong Yang12Shangli Cai13Yong He14Department of Respiratory Disease Daping Hospital, Army Medical University Chongqing ChinaDepartment of Intensive care unit Daping Hospital, Army Medical University Chongqing ChinaDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University Changsha ChinaDepartment of Respiratory Disease Daping Hospital, Army Medical University Chongqing ChinaDepartment of Respiratory Disease Daping Hospital, Army Medical University Chongqing ChinaDepartment of Respiratory Disease Daping Hospital, Army Medical University Chongqing ChinaDepartment of Respiratory Disease Daping Hospital, Army Medical University Chongqing ChinaDepartment of Respiratory Disease Daping Hospital, Army Medical University Chongqing ChinaDepartment of Respiratory Disease Daping Hospital, Army Medical University Chongqing ChinaBurning Rock Biotech Guangzhou ChinaDepartment of Respiratory Disease Daping Hospital, Army Medical University Chongqing ChinaRespiratory Medicine Department, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health The First Affiliated Hospital of Guangzhou Medical University Guangzhou ChinaDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University Changsha ChinaBurning Rock Biotech Guangzhou ChinaDepartment of Respiratory Disease Daping Hospital, Army Medical University Chongqing ChinaAbstract Background Plasma and tissue biopsy have both used for targeting actionable driver gene mutations in lung cancer, whose concordance is imperfect. A reliable method to predict the concordance is urgently needed to ease clinical application. Methods A total of 1012 plasma samples, including 519 with paired‐tissue biopsy samples, derived from lung adenocarcinoma patients were retrospectively enrolled. We assessed the associations of several clinicopathological characteristics and serum tumor markers with the concordance between plasma and tissue biopsies. Results When carcinoembryonic antigen (CEA) levels were higher than thresholds of 15.01 ng/ml and 51.15 ng/ml, the positive predictive value of concordance reached 90% and 95%, respectively. When CEA levels were lower than thresholds of 5.19 ng/ml and 3.26 ng/mL, the negative predictive value of concordance reached 45% and 50%. The performance of CYFRA21‐1 in predicting concordance was similar but inferior to CEA (AUC: 0.727 vs. 0.741, p = 0.633). The performance of CEA combined with CYFRA21‐1 in predicting the concordance was similar to that of the combination of independent factors derived from the LASSO regression model (AUC: 0.796 vs. 0.818, p = 0.067). CEA (r = 0.47, p < 0.01) and CYFRA21‐1 levels (r = 0.45, p < 0.05) were significantly correlated with the maximum variant allele frequency, respectively. Conclusions CEA combined with CYFRA21‐1 could effectively predict the concordance between plasma and tissue biopsies, which could be used for evaluating the priority of plasma and tissue biopsies for gene testing to timely guide clinical applications in advanced lung adenocarcinoma patients.https://doi.org/10.1002/cam4.5410circulating tumor DNAliquid biopsynext generation sequencingnon‐small cell lung cancerserum tumor marker |
| spellingShingle | Chenglong Zhao Jianghua Li Yongchang Zhang Rui Han Yubo Wang Li Li Yimin Zhang Mengxiao Zhu Jie Zheng Haiwei Du Chen Hu Chengzhi Zhou Nong Yang Shangli Cai Yong He The rational application of liquid biopsy based on next‐generation sequencing in advanced non‐small cell lung cancer Cancer Medicine circulating tumor DNA liquid biopsy next generation sequencing non‐small cell lung cancer serum tumor marker |
| title | The rational application of liquid biopsy based on next‐generation sequencing in advanced non‐small cell lung cancer |
| title_full | The rational application of liquid biopsy based on next‐generation sequencing in advanced non‐small cell lung cancer |
| title_fullStr | The rational application of liquid biopsy based on next‐generation sequencing in advanced non‐small cell lung cancer |
| title_full_unstemmed | The rational application of liquid biopsy based on next‐generation sequencing in advanced non‐small cell lung cancer |
| title_short | The rational application of liquid biopsy based on next‐generation sequencing in advanced non‐small cell lung cancer |
| title_sort | rational application of liquid biopsy based on next generation sequencing in advanced non small cell lung cancer |
| topic | circulating tumor DNA liquid biopsy next generation sequencing non‐small cell lung cancer serum tumor marker |
| url | https://doi.org/10.1002/cam4.5410 |
| work_keys_str_mv | AT chenglongzhao therationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer AT jianghuali therationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer AT yongchangzhang therationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer AT ruihan therationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer AT yubowang therationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer AT lili therationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer AT yiminzhang therationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer AT mengxiaozhu therationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer AT jiezheng therationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer AT haiweidu therationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer AT chenhu therationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer AT chengzhizhou therationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer AT nongyang therationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer AT shanglicai therationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer AT yonghe therationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer AT chenglongzhao rationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer AT jianghuali rationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer AT yongchangzhang rationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer AT ruihan rationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer AT yubowang rationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer AT lili rationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer AT yiminzhang rationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer AT mengxiaozhu rationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer AT jiezheng rationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer AT haiweidu rationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer AT chenhu rationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer AT chengzhizhou rationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer AT nongyang rationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer AT shanglicai rationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer AT yonghe rationalapplicationofliquidbiopsybasedonnextgenerationsequencinginadvancednonsmallcelllungcancer |